Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Zhongguo Zhong Yao Za Zhi ; 49(2): 509-517, 2024 Jan.
Artículo en Chino | MEDLINE | ID: mdl-38403326

RESUMEN

This study investigated the absorption profile of Wuwei Qingzhuo San in different intestinal segments and the absorption characteristics of its alkaloids(piperine, piperanine, piperlonguminine, and dihydropiperlonguminine). The everted gut sac model was established, and the chemical components of Wuwei Qingzhuo San in different intestinal segments were detected by UPLC-Q-TOF-MS. The content of piperine, piperanine, piperlonguminine, and dihydropiperlonguminine in intestinal absorption fluid was determined by UPLC-Q-TRAP-MS and the absorption parameters were calculated. The absorption characteristics in different intestinal segments at different time were analyzed. As a result, 27, 27, 8, and 6 absorbent components from Wuwei Qingzhuo San were detected in the intestinal cyst fluid of jejunum, ileum, duodenum, and colon by UPLC-Q-TOF-MS technology, respectively. It was also found that piperine, piperanine, piperlonguminine, and dihydropiperlonguminine from Wuwei Qingzhuo San showed linear absorption in various intestinal segments, with r values exceeding 0.9. In terms of absorption content, the components were ranked as piperine>piperanine>dihydropiperlonguminine>piperlonguminine in various intestinal segments, but the absorption rate and mechanism of each component varied. The results demonstrate that the absorption of the components of Wuwei Qingzhuo San in different intestinal segments is selective and is not a simple semi-permeable membrane permeation process.


Asunto(s)
Alcaloides , Piperidinas , Alcamidas Poliinsaturadas , Benzodioxoles , Absorción Intestinal
2.
Food Funct ; 13(14): 7448-7472, 2022 Jul 18.
Artículo en Inglés | MEDLINE | ID: mdl-35766524

RESUMEN

Edible medicinal plants are important sources for the development of health beneficial products and drugs. Several species of the genus Spatholobus are considered as medicinal and food homologous plants in various Asian countries for the treatment of menstrual pain, anemia, paralysis, arthralgia, etc. Regarding this genus, mounting investigations on different aspects have been conducted; however, a comprehensive review about these findings is yet to be compiled. Herein, we reviewed the up-to-date information on the botanical description, distribution, ethnopharmacology, phytochemistry, pharmacology, and toxicology of the Spatholobus species for the first time to support their development potential. Thus far, 175 phytochemicals have been isolated, and flavonoids are the predominant constituents. Furthermore, 141 compounds show the ideal characteristic behavior of a drug-like molecule. Besides, the compounds and crude extracts of this genus have been demonstrated to exert a wide range of in vitro and in vivo bioactivities, such as antitumor activity, antioxidant activity, antiinflammatory activity, antiischemic activity, antimicrobial activity, and neuroprotective activity. Toxicity studies have revealed that Spatholobus species seem to have no apparent toxic effects. Even so, the need for in-depth studies to reveal the scientific connotation of the widely documented traditional actions, the structure-activity relationship of the bioactive compounds, and the systematic toxic reactions are warranted, and also to provide essential evidence for the beneficial use of Spatholobus plants and developing novel health care products and therapeutic drug from this genus.


Asunto(s)
Fabaceae , Plantas Medicinales , Etnofarmacología , Fitoquímicos/química , Fitoterapia , Extractos Vegetales/química
3.
Biomed Res Int ; 2021: 6681491, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34195279

RESUMEN

BACKGROUND: Although hypothyroidism during pregnancy may develop grave outcomes for both mothers and offspring, management of which is still a challenge due to the insufficient understanding of this disease. The close correlation between hypothyroidism and preeclampsia is well documented, suggesting that preeclampsia is a potential risk factor for the development of maternal hypothyroidism. However, the exact role of preeclampsia in gestational hypothyroidism is still obscure. OBJECTIVE: In this study, we explored the possible mechanisms of the effect of preeclampsia on thyroid function of maternal rats. METHODS: Thirty pregnant rats were randomly divided into normal pregnancy control (NOP), preeclampsia (PE), and preeclampsia supplemented with amlodipine besylate (PEAml). NG-Nitro-L-arginine-methyl ester was used to induce preeclamptic symptoms. On gestational day 21, rats were sacrificed, and then, the ultrastructure of the thyroid gland, type 1 iodothyronine deiodinase (Dio1) expression, and serum-free thyroxine (FT4), free triiodothyronine (FT3), and thyroid stimulation hormones (TSH) were assessed. RESULTS: Compared to NOP rats, results of PE rats showed that thyroid follicular cells' ultrastructure was damaged; both hepatic Dio1 mRNA and protein levels were decreased. Interestingly, these changes were ameliorated in PEAml rats. Additionally, FT4, FT3, and TSH levels have no significant differences among groups. CONCLUSION: These findings indicated that preeclampsia could disrupt synthesis, secretion, and metabolism function of thyroid hormones by damaging thyroid follicular cells and interfering Dio1 expression.


Asunto(s)
Hipotiroidismo/metabolismo , Yoduro Peroxidasa/metabolismo , Hígado/enzimología , Preeclampsia/metabolismo , Glándula Tiroides/ultraestructura , Hormonas Tiroideas/sangre , Animales , Femenino , Hipotiroidismo/complicaciones , NG-Nitroarginina Metil Éster/metabolismo , Embarazo , Preñez , Ratas , Ratas Sprague-Dawley , Factores de Riesgo , Tirotropina/sangre , Tiroxina/sangre , Factores de Tiempo , Triyodotironina/sangre
4.
Drug Des Devel Ther ; 14: 4263-4276, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33116414

RESUMEN

PURPOSE: Anisodine hydrobromide (Ani) is isolated from the medicinal plant Anisodus tanguticus (Maxim.) Pascher for clinical use. Although considerable research regarding Ani has been reported, the safety profiles of Ani are currently unknown. This study investigated the cardiorespiratory effects of Ani in conscious dogs to provide clinicians a detailed safety profile of Ani on the cardiorespiratory system. MATERIALS AND METHODS: Using the Latin square design, the study was divided into six phases, where in each phase, six telemetered beagle dogs received one dose of normal saline or sotalol hydrochloride or Ani (0.1, 0.4, 1.6, or 6.4 mg/kg). Electrocardiogram, blood pressure (BP) and respiratory parameters were collected before and after administration for 24 hours. Statistical comparisons were performed at scheduled time-points. RESULTS: The heart rate was significantly increased, PR and QTCV intervals were significantly shortened in Ani 0.4, 1.6, 6.4 mg/kg treatment group after drug administration. Compared with the saline group, a significant increase in heart rate and shortening of PR, QTCV intervals were observed in the Ani 1.6, 6.4 mg/kg treatment groups from 5 min to 4 h time-points. Diastolic and mean BP were significantly increased in Ani 1.6, 6.4 mg/kg from 1 h to 2 h time-points compared to those of the saline control. Accelerated breathing was observed in the first 20 min after Ani 0.4, 1.6, and 6.4 mg/kg treatment, although not statistically significant. Furthermore, no significant differences were observed in any of the corresponding indexes of Ani 0.1 mg/kg treatment group at different time-points compared to those of the saline group. CONCLUSION: Ani may have adverse effects on the cardio-respiratory systems of dogs at doses above 0.4 mg/kg, whereas Ani 0.1 mg/kg was devoid of potentially deleterious effects on cardiorespiratory function.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Sistema Cardiovascular/efectos de los fármacos , Respiración/efectos de los fármacos , Derivados de Escopolamina/farmacología , Antagonistas Adrenérgicos beta/farmacología , Animales , Antiinflamatorios no Esteroideos/toxicidad , Presión Sanguínea/efectos de los fármacos , Estado de Conciencia , Perros , Electrocardiografía , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Derivados de Escopolamina/toxicidad , Sotalol/farmacología , Telemetría
5.
Medicine (Baltimore) ; 99(31): e21496, 2020 Jul 31.
Artículo en Inglés | MEDLINE | ID: mdl-32756183

RESUMEN

BACKGROUND: Postpartum depression (PPD) is one of the most common mental disorders in women following childbirth with heightened prevalence across the globe. Both pharmacotherapy and non-pharmacological interventions are effective for PPD. However, due to the concerns about the side effect on the mother and child of pharmacological treatments, most of women with PPD choose non-pharmacological therapies as their first line option. Prescription of these non-drug approaches should be guided by high quality evidence. Therefore, this network meta-analysis aims to compare, rank and interpret existed non-pharmacological evidence for the effective treatment of women with PPD. METHODS: Electronic bibliographic databases including EMBASE, PubMed, Scopus, The Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI),VIP Database, Wanfang Database and Chinese Biomedical Literature Database will be searched for relevant randomized controlled trials (RCTs) of non-pharmacological interventions for PPD. Heterogeneity and inconsistencies will be analyzed by I statistic and Z test, respectively. We will assess the quality of evidence by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) and evaluate the risk of bias according to Cochrane risk of bias tool. R software 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) will be used to conduct a network meta-analysis. RESULTS: Formal ethical approval is not required, because the present study is a meta-analysis based on existed studies. The findings of this research will be reported in a recognized journal. CONCLUSION: The review results will ascertain the hierarchy of effectiveness of different non-pharmacological approaches for PPD, and systematically provide suggests for physicians and patients. TRIAL REGISTRATION NUMBER: PROSPERO CRD42020166801.


Asunto(s)
Terapias Complementarias/métodos , Depresión Posparto/terapia , Femenino , Humanos , Metaanálisis en Red , Embarazo , Proyectos de Investigación , Revisiones Sistemáticas como Asunto , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA